
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. reported a year-over-year increase in operating expenses, amounting to $36.4 million, which highlights the company's investment in growth strategies. The company demonstrated strong financial performance in its third-quarter report, surpassing revenue expectations and raising the midpoint of its guidance, while also increasing gross margin guidance for 2025 from 72-74% to 76-77%. Furthermore, potential upside drivers such as the growth of the light adjustable lenses (LAL) installed base, higher utilization rates, and improved margins suggest a favorable outlook for RxSight's stock.
Bears say
The financial data for RxSight Inc. indicates a declining trend in operational efficiency and revenue generation, as evidenced by a decrease in monthly utilization of light adjustable lenses (LALs) per laser delivery device (LDD) from 8.7 in the previous quarter to 8.0 in the current quarter, and a drop from 10.1 in the same quarter last year. The company has also issued guidance for fiscal year 2026 revenue that falls short of both internal and market expectations, projecting revenue of $120-135 million, which represents a decline of up to 11% year-over-year. Additionally, the anticipated impact of increased inventory costs on gross margins, coupled with a significant drop in LDD placements and overall sales volumes, raises concerns about the company's future financial stability and growth prospects.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares